ArticleGenes and immunity2010
HLA-class I markers and multiple sclerosis susceptibility in the Italian population.
Article in Genes and immunity, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 61 citations in OpenAlex.
- High Resolution Haplotype Analyses of Classical HLA Genes in Families With Multiple Sclerosis Highlights the Role of HLA-DP Alleles in Disease Susceptibility.Frontiers in immunology · 2021Trial
- Autoimmune HLA alleles and neoantigens predict myelodysplastic syndrome outcomes after allogeneic HSCT: A CIBMTR analysis.iScience · 2026Article
- Machine Learning Methods for Classifying Multiple Sclerosis and Alzheimer's Disease Using Genomic Data.International journal of molecular sciences · 2025Article
- Distribution of Major HLA-A, -B, -DR, and -DQ Loci Potentially Associated with Multiple Sclerosis in a Healthy Population from Southern Morocco.Clinics and practice · 2025Article
- Variable patterns of retrotransposition in different HeLa strains provide mechanistic insights into SINE RNA mobilization processes.Nucleic acids research · 2024Article
- Myeloid antigen-presenting cells in neurodegenerative diseases: a focus on classical and non-classical MHC molecules.Frontiers in neuroscience · 2024Review
- High resolution HLA analysis reveals independent class I haplotypes and amino-acid motifs protective for multiple sclerosis.Genes and immunity · 2019Article
- Article
- The immunogenetics of multiple sclerosis: A comprehensive review.Journal of autoimmunity · 2015Review
- Natural killer cells and their receptors in multiple sclerosis.Brain : a journal of neurology · 2013Review
- HLA class I & II alleles in multiple sclerosis patients from Puerto Rico.Boletin de la Asociacion Medica de Puerto Rico · 2013Article
- Risk of developing chronic lymphocytic leukemia is influenced by HLA-A class I variation.Leukemia · 2013Article
- Association of genetic markers with CSF oligoclonal bands in multiple sclerosis patients.PloS one · 2013Article
- Dendritic cells and multiple sclerosis: disease, tolerance and therapy.International journal of molecular sciences · 2012Review
- Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis.Genes and immunity · 2012Article
- Article
- Importance of human leukocyte antigen (HLA) class I and II alleles on the risk of multiple sclerosis.PloS one · 2012Article
- HLA (A-B-C and -DRB1) alleles and brain MRI changes in multiple sclerosis: a longitudinal study.Genes and immunity · 2011Article
- Aggregation of multiple sclerosis genetic risk variants in multiple and single case families.Annals of neurology · 2011Article
- Heterogeneity in multiple sclerosis: scratching the surface of a complex disease.Autoimmune diseases · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous studies reported an association with multiple sclerosis (MS) of distinct HLA-class I markers, namely HLA-A*02, HLA-Cw*05 and MOG-142L. In this work, we tested the association with MS of A*02 and Cw*05 in 1273 Italian MS patients and 1075 matched controls, which were previously analyzed for MOG-142, and explored the relationship among these three markers in modulating MS risk. HLA-A*02 conferred a statistically robust MS protection (odds ratio, OR=0.61; 95% confidence intervals, CI=0.51-0.72, P<10(-9)), which was independent of DRB1*15 and of any other DRB1* allele and remained similar after accounting for the other two analyzed class I markers. Conversely, the protective effect we previously observed for MOG-142L was secondary to its linkage disequilibrium with A*02. Cw*05 was not associated considering the whole sample, but its presence significantly enhanced the protection in the HLA-A*02-positive group, independently of DRB1: the OR conferred by A*02 in Cw*05-positive individuals (0.22, 95% CI=0.13-0.38) was significantly lower than in Cw*05-negative individuals (0.69, 95% CI=0.58-0.83) with a significant (P=4.94 x 10(-5)) multiplicative interaction between the two markers. In the absence of A*02, Cw*05 behaved as a risk factor, particularly in combination with DRB1*03 (OR=3.89, P=0.0006), indicating that Cw*05 might be a marker of protective or risk haplotypes, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.